Therapy for Restoration of Impaired Insulin Secretion
- Detailed Technology Description
- This invention describes the use of ebselen in the treatment for diabetes and hypoglycemia, which has been shown to improve glucose-stimulated insulin secretion (GSIS) in islets.
- Others
-
- Patent application No. US 2015/0297564
- X. Wang, J-W Yun, and X. G. Lei. (2014). Glutathione peroxidase mimic ebselen improves glucose-stimulated insulinsecretion in murine islets. Antioxidants& Redox Signaling. Vol.20(2): 191-203. DOI:10.1089/ars.2013.5361
- X.Wang, et al. (2011). Knockouts of SOD1 and GPX1 Exert Different Impactson Murine Islet Function and Pancreatic Integrity. Antioxidants & Redox Signaling. Vol.14(3):391-401. DOI: 10.1089/ars.2010.3302.
- *Abstract
-
Insulin resistance has long been considered the cause of type 2 diabetes, however defective insulin secretion has been more recently suggested as a factor in this prevalent disease. In a healthy individual, pancreatic islet beta cells respond to high blood glucose concentrations by secreting their stored insulin (GSIS).
Ebselen is a mimic of glutathione peroxidase and is well-known for its antioxidant activity. It has been trialed therapeutically for conditions such as conjunctivitis, infections, and ischemic stroke, and has the potential to be repurposed for treatment of type 2 diabetes.
The inventor demonstrated proof of principle in mice with four different genotypes, which showed improved GSIS after they were treated with ebselen.
Potential Application:
Treatment for type 2 diabetes and hyperglycemia.
Advantages:
- Restores GSIS.
- Ebselen already has been trialed for therapeutic use in treating oxidative injuries.
- *Licensing
- PhillipOwh607-254-4508po62@cornell.edu
- Country/Region
- USA
